Flag of the European Union EU Clinical Trials Register Help

Clinical trials for pH

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,391 result(s) found for: pH. Displaying page 8 of 70.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2011-006342-32 Sponsor Protocol Number: 75111-10114 Start Date*: 2013-06-11
    Sponsor Name:EORTC
    Full Title: Pertuzumab + trastuzumab (PH) versus PH plus metronomic chemotherapy (PHM) in the elderly HER2+ metastatic breast cancer population who may continue on T-DM1 alone following disease progression whi...
    Medical condition: Newly diagnosed or recurrent (after surgery) stage IV (TNM/AJCC v.7) HER-2 positive (IHC 3+ or or HER-2 gene amplification by in situ hybridization) invasive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) IT (Completed) PT (Completed) NL (Completed) GB (GB - no longer in EU/EEA) SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-003276-39 Sponsor Protocol Number: PR(AG)293/2019 Start Date*: 2019-11-12
    Sponsor Name:VALL HEBRON UNIVERSITY HOSPITAL
    Full Title: Liver impairment recovery related to parenteral nutrition with omega-3 fatty acids: randomized clinical trial.
    Medical condition: Critically ill adult patients with parenteral nutrition and liver parameters altered.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-003520-10 Sponsor Protocol Number: BAY63-2521/12166 Start Date*: 2006-10-20
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, non-randomized, non-blinded, non-controlled study to investigate the impact of multiple doses of BAY 63 2521 on safety, tolerability, pharmacokinetics, and pharmacodynamics in patien...
    Medical condition: Subjects with PH due to • Pulmonary arterial hypertension (PAH) [Venice protocol] or • Chronic thrombembolic PH (CTEPH)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004049-27 Sponsor Protocol Number: 2008-004049-27 Start Date*: 2009-03-18
    Sponsor Name:Karolinska Univsjukhuset
    Full Title: Vätskebehandling vid akut diabetessjukdom (Diabetes ketoacidos)
    Medical condition: Studien kommer bedrivas på akut diabetessjukdom (Diabetisk ketoacidos). Studien kommer att följa patienten från akuten till IVA tills dess att ph>7,3. Gängse praxis angående medicinsk behandling ko...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012671 Diabetic ketoacidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000705-86 Sponsor Protocol Number: 01-2020 Start Date*: 2020-04-26
    Sponsor Name:VALL HEBRON UNIVERSITY HOSPITAL
    Full Title: Control of inflammatory parameters with omega-3 fatty acid supplementation in adult patients with parenteral nutrition and respiratory infection by SARS-CoV-2: randomized clinical trial COVID-19
    Medical condition: Critically ill adult patients with parenteral nutrition and respiratory infection by SARS-COV-2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000142-22 Sponsor Protocol Number: 148-2016 Start Date*: 2017-05-24
    Sponsor Name:Helm AG
    Full Title: Assessment of therapeutical equivalence of a newly developed vaginal tablet containing 10 μg of estradiol in comparison with a marketed reference product (Vagifem®) – a double-blind, double-dummy, ...
    Medical condition: Investigation of efficacy, safety and tolerability of estradiol vaginal tablets in postmenopausal women with vaginal atrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10047782 Vulvovaginal atrophy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016613-22 Sponsor Protocol Number: OxyPeP-001 Start Date*: 2010-06-14
    Sponsor Name:PeP-Tonic Medical AB
    Full Title: A double-blind, placebo controlled multi-centre study to evaluate the effects of topical Oxytocin on vaginal atrophy in postmenopausal women.
    Medical condition: Vaginal atrophy in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    12.1 10047782 Vulvovaginal atrophy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005107-42 Sponsor Protocol Number: GIMEMA LAL1205 Start Date*: 2006-09-29
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL ADULTO
    Full Title: A Phase II Multicenter Study on the Treatment of Adult de novo Philadelphia Chromosome Positive Ph Acute Lymphoblastic Leukemia ALL with the Protein Tyrosine Kinase Inhibitor BMS-354825.
    Medical condition: Treatment of Adult de novo Philadelphia Chromosome Positive Ph Acute Lymphoblastic Leukemia ALL
    Disease: Version SOC Term Classification Code Term Level
    6.1 10000846 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006632-67 Sponsor Protocol Number: CHUBX2021/36 Start Date*: 2022-03-14
    Sponsor Name:CHU de Bordeaux
    Full Title: Alkalinization of adrenalized lidocaine in extending epidural analgesia for extremely urgent cesarean section during labor: a randomized controlled trial.
    Medical condition: epidural analgesia for extremely urgent cesarean
    Disease: Version SOC Term Classification Code Term Level
    20.0 10036585 - Pregnancy, puerperium and perinatal conditions 10036585 Pregnancy, puerperium and perinatal conditions SOC
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001838-29 Sponsor Protocol Number: TEATE Start Date*: 2015-01-08
    Sponsor Name:"G. d'Annunzio" University
    Full Title: PrevenTion of contrast‐inducEd nephroAThy with urinE alkalinization: the TEATE study
    Medical condition: contrast‐induced nephroathy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10022117 - Injury, poisoning and procedural complications 10010836 Contrast media reaction PT
    17.0 10038359 - Renal and urinary disorders 10029155 Nephropathy toxic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005124-15 Sponsor Protocol Number: CAMN107AIC05 Start Date*: 2013-02-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A prospective, randomized, open label two arm Phase III study to evaluate treatment free remission (TFR) rate in patients with Philadelphia chromosome-positive CML after two different durations of ...
    Medical condition: Adult patients with Ph+ chronic phase CML that have been treated with Imatinib for at least 2 years, are in CCyR, but have not achieved MR4.0 at study entry.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SK (Completed) SE (Completed) HU (Completed) IT (Completed) DE (Completed) NO (Completed) PT (Completed) FI (Completed) ES (Completed) IE (Completed) CZ (Completed) BG (Completed) BE (Completed) GR (Completed) DK (Completed) SI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000602-17 Sponsor Protocol Number: CABL001A2001B Start Date*: 2021-08-10
    Sponsor Name:Novartis Pharma AG
    Full Title: An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit fr...
    Medical condition: CML-CP (at the end of parent study) who are currently participating in an asciminb Novartis sponsored study (parent study)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Ongoing) BG (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002156-17 Sponsor Protocol Number: GIMEMALAL1104 Start Date*: 2007-05-22
    Sponsor Name:G.I.M.E.M.A. GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL'ADULTO
    Full Title: ''Geriatric assessment adapted'' therapy for the treatment of Ph-negative Acute lymphoblastic Leukemia in elder patients.
    Medical condition: Acute lymphoblastic leukemia Ph- of the elder
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000846 Acute lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001102-34 Sponsor Protocol Number: CML1315 Start Date*: 2015-09-15
    Sponsor Name:FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS
    Full Title: Optimizing Ponatinib USe (OPUS). Studio GIMEMA di fase 2 sull¿efficacia e sul profilo di rischio di ponatinib, 30 mg al giorno, in pazienti con Leucemia Mieloide Cronica (LMC) in Fase Cronica, resi...
    Medical condition: Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009013 Chronic myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000072-16 Sponsor Protocol Number: BAY63-2521/11348 Start Date*: Information not available in EudraCT
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with Chronic...
    Medical condition: Chronic Thromboembolic Pulmonary Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037406 Pulmonary hypertension secondary LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) GB (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed) IT (Completed) BE (Completed) CZ (Completed) SK (Completed) PT (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-002601-69 Sponsor Protocol Number: CA180-013 Start Date*: 2005-01-25
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study to Determine the Activity of BMS-354825 in Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Disease that is Resistant to High Dose Ima...
    Medical condition: Chronic phase Philadelphia chromosome-positive chronic myeloid leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) SE (Completed) FI (Completed) GB (Completed) IE (Completed) IT (Completed) BE (Completed) ES (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-005787-42 Sponsor Protocol Number: ITFE-2092-C1 Start Date*: 2016-08-10
    Sponsor Name:ITF Research Pharma SLU
    Full Title: A Phase 2, Dose-ranging, 12-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (...
    Medical condition: Vulvovaginal atrophy in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000024113 10047782 Vulvovaginal atrophy LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) CZ (Completed) HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-011169-98 Sponsor Protocol Number: GS-US-300-0128 Start Date*: 2009-11-03
    Sponsor Name:Gilead Sciences, Inc
    Full Title: ARTEMIS-PH: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects with Idiopathic Pulmonary Fibr...
    Medical condition: Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021240 Idiopathic pulmonary fibrosis LLT
    12.0 10037400 Pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) GB (Prematurely Ended) IT (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-001318-92 Sponsor Protocol Number: AP24534-15-303 Start Date*: 2015-11-03
    Sponsor Name:ARIAD Pharmaceuticals, Inc.
    Full Title: A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib
    Medical condition: Chronic Phase Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10054352 Chronic phase chronic myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) DK (Prematurely Ended) CZ (Completed) PT (Completed) FR (Completed) AT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-002476-92 Sponsor Protocol Number: 20120215 Start Date*: 2015-06-29
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open-label, Controlled Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidatio...
    Medical condition: Patients with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse B-precursor ALL (as defined by I-BFM SG/IntReALL criteria)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.1 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BE (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) FR (Completed) NL (Completed) Outside EU/EEA GR (Completed) NO (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 02 17:07:42 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA